Excisional wound repair is a multi-billion dollar market that is inadequately served with current treatment options. MicroCures believes that its proprietary cell movement acceleration platform, led by MCR-111, represents a fundamentally new and disruptive technology. It provides a much-needed alternative to today’s complex, potentially unsafe and often unproven regenerative medicine treatments that are used for wound healing.
MCR-111 is applied topically to the damaged tissue resulting in an accelerated burst of healing, after which the treated cells return to their normal rate of movement within 48 hours with no apparent long-term change to cell behavior. The MCR-111 treatment can be repeated over a multi-day period to optimize speed and quality of tissue repair after injury.